Leap Therapeutics, Inc.
NASDAQ:LPTX
Overview | Financials
Company Name | Leap Therapeutics, Inc. |
Symbol | LPTX |
Currency | USD |
Price | 2.95 |
Market Cap | 113,037,805 |
Dividend Yield | 0% |
52-week-range | 1.68 - 5 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Douglas E. Onsi J.D. |
Website | https://www.leaptx.com |
An error occurred while fetching data.
About Leap Therapeutics, Inc.
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics, Inc. has an
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD